SEARCH

SEARCH BY CITATION

References

  • 1
    Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the national heart, lung, and blood institute. Circulation 2006;113:23632372.
  • 2
    Davidson P, Stocks N, Aggarwal A, et al. Reducing risk in heart disease: An expert guide to clinical practice for secondary prevention of coronary heart disease, Updated 2012. National heart foundation of Australia and Cardiac Society of Australia and New Zealand 2012.
  • 3
    Australian Resuscitation Council NZRC. Acute coronary syndromes: Initial medical therapy. ARC and NZRC guideline 2011. Emerg Med Australas 2011;23:308311.
  • 4
    Giorda C, Maggini M, Alegiani SS, Turco S, Raschetti R. Secondary prevention of coronary artery disease in high-risk diabetic patients. Nutr Metab Cardiovasc Dis 2003;13:238243.
  • 5
    Joynt KE, Huynh L, Amerena JV, et al. Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes. Heart 2009;95:14421448.
  • 6
    Pheatt N, Brindis G, Levin E. Putting heart disease guidelines into practice: Kaiser permanente leads the way. The Permanente Journal 2003;7:1823.
  • 7
    Ajani AE, Szto G, Duffy SJ, et al. The foundation and launch of the Melbourne interventional group: A collaborative interventional cardiology project. Heart Lung Circ 2006;15:4447.
  • 8
    McNeil JJ, Evans SM, Johnson NP, Cameron PA. Clinical-quality registries: Their role in quality improvement. Med J Aust 2010;192:244245.
  • 9
    Skillington P. A national cardiac surgery database: Current achievements and future challenges. Heart Lung Circ 2001;10:S2S4.
  • 10
    Graves SE, Davidson D, Ingerson L, et al. The Australian orthopaedic association national joint replacement registry. Med J Aust 2004;180:S31S34.
  • 11
    Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985;4:8790.
  • 12
    Zeymer U, James S, Berkenboom G, et al. Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI. Eur J Prev Cardiol 2013;20:218228.
  • 13
    Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Euroaspire III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121137.
  • 14
    Lee JH, Yang DH, Park HS, et al. Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea acute myocardial infarction registry: Prescription rate, predictors, and prognostic value. Am Heart J 2010;159:10121019.
  • 15
    Prugger C, Heidrich J, Wellmann J, et al. Trends in cardiovascular risk factors among patients with coronary heart disease: Results from the Euroaspire I, II, and III surveys in the Munster region. Dtsch Arztebl Int 2012;109:303310.
  • 16
    Boden WE, Flather MD, Bhatt DL. Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: Putting the charisma trial into therapeutic perspective. Cardiovasc Drugs Ther 2010;24:207216.
  • 17
    Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e637Se668S.
  • 18
    Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:10351041e1.
  • 19
    Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: Frequency, predictors and associations with death and myocardial infarction–a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J 2011;32:23762386.
  • 20
    Prugger C, Keil U, Wellmann J, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: Results from the Euroaspire III survey. J Hypertens 2011;29:16411648.
  • 21
    Murphy BM, Worcester MU, Goble AJ, et al. Lifestyle and physiological risk factor profiles six weeks after an acute cardiac event: Are patients achieving recommended targets for secondary prevention? Heart Lung Circ 2011;20:446451.
  • 22
    Nguyen HL, Goldberg RJ, Gore JM, et al. Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: Perspectives from a multinational registry. Coron Artery Dis 2010;21:336344.
  • 23
    Dallongevillle J, De Bacquer D, Heidrich J, et al. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart 2010;96:17441749.
  • 24
    Onuma Y, Kukreja N, Ramcharitar S, Hochadel M, Gitt A, Serruys P. Interventional treatment in diabetics in the era of drug-eluting stents and compliance to the ESC guidelines: Lessons learned from the Euro heart survey programme. EuroIntervention 2009;4:578587.
  • 25
    Aliprandi-Costa B, Ranasinghe I, Chow V, et al. Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000–2007. Med J Aust 2011;195:116121.
  • 26
    Bakhai A, Ferrieres J, Iniguez A, Schmitt C, Sartral M, Belger M, Zeymer U. International data on supportive therapies at 1 year in acute coronary syndrome patients undergoing PCI: Results from the Aptor study. Eur J Cardiovasc Prev Rehabil 2011;18:518525.
  • 27
    Cooney MT, Kotseva K, Dudina A, De Backer G, Wood D, Graham I. Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. Eur J Prev Cardiol 2013;20:686691.